Shares of ContraVir Pharmaceuticals Inc (OTC BB: CTRV), engaged in the development and commercialization of targeted antiviral therapies, recorded over 15.0% gain during each of the past two consecutive trading sessions with significant number of shares exchanging hands. CTRV was among the top performers in U.S. healthcare sector after gaining 16.2% and closed at $4.94 Friday, while recording significant trading volumes of 130,722 shares. The rise in the stock’s price is attributable to the recent announcement made by CTRV that its licensing partner, Chimerix Inc., has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent titled, “Nucleoside Phosphonate Salts.” The patent covers composition of matter for CTRV’s HBV compound CMX157. During the past 5-trading sessions, CTRV gained 88.5% with daily average trading volumes of 78,955 shares, while the stock accumulated 119.5% gain during the past one month with daily average trading volumes of 28,660 shares. The stock is up 122.2% year-to-date.
Company Description:
ContraVir Pharmaceuticals Inc. (OTC BB: CTRV) manufactures biopharmaceuticals. The company specializes on the development of drugs to treat herpes zoster or shingles. ContraVir provides services worldwide.
1-Year Stock Chart:
Source: Bloomberg
